Samuel S. Kintz
Co-Founder & Head of PipelineMr. Samuel S. Kintz, M.B.A., also known as Sam, is Chair of Arpeggio Biosciences, Inc. from December 2025. Mr. Kintz is Co-Founder and Head of Pipeline and was Secretary & CEO & Director of Enliven Therapeutics, Inc. until December 11, 2025. He had served as Former Enliven’s President and Chief Executive Officer and a Directors since June 2019 and was appointed as the President, Chief Executive Officer and a Directors of Company in connection with the closing of the Merger on February 23, 2023. Prior to co-founding Enliven, he was an Executive Director of Research at AbbVie and the Head of Research at AbbVie Stemcentrx. Sam started at Stemcentrx as Senior Director, Strategy and Business Development. He has also served as Vice President, Business Development and Applications, at Biodesy, a South San Francisco-based biotech startup developing and commercializing novel protein conformation technology for small-molecule drug discovery. Additionally, Sam has worked at Roche Venture Fund, where he triaged and sourced investment opportunities in the life sciences industry. He has also worked as a medicinal chemist at Genentech, where he designed and synthesized small-molecule drugs for the treatment of cancer and neurodegenerative diseases. He earned both an M.B.A. and a B.S. in Chemistry, with Honors, from Stanford University.
Positions
- Company NameEnliven Therapeutics, Inc.Stock CodeELVNPositionCo-Founder & Head of PipelineColleagues
- RARichard A. FairCEO, President & Director
- BHBenjamin HohlCFO & Head of Corporate Development
- HLHelen Louise CollinsChief Medical Officer
- JPJoseph P. LyssikatosCo-Founder & Research Fellow
- RGRishi GuptaIndependent Director
- JBJacob B. BauerIndependent Director
- SGScott GarlandDirector
- MKMika Kakefuda DerynckIndependent Director
